Advertisement

Journal of Neuro-Oncology

, Volume 30, Issue 3, pp 257–265 | Cite as

Therapy of primary central nervous system lymphoma with pre-irradiation methotrexate, cyclophosphamide, doxorubicin, vincristine, and dexamethasone (MCHOD)

  • Jon Glass
  • Chaim Shustik
  • Fred H. Hochberg
  • Lawrence Cher
  • Michael L. Gruber
Clinical Study

Abstract

Prior studies have suggested that pre-irradiation methotrexate (MTX)-based chemotherapy improves duration of response and survival in primary central nervous system lymphoma (PCNSL). To circumvent the potential emergence of drug resistance, we combined high-dose MTX with agents highly active against systemic lymphoma. Patients received three week cycles of CHOD (cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, and vincristine 1.4 mg/m2 [2 mg maximum] on day 1; dexamethasone 10 mg/m2 days 1–5), and MTX (3.5 gm/m2) with leucovorin rescue on day 8 (or on recovery from the CHOD nadir). Whole brain irradiation (WBRT) was planned after at least three cycles. Eighteen patients were treated. Complete responses were seen in eleven patients, and partial responses in three. Four progressed during therapy, three succumbing to progressive disease and one subsequently responding to WBRT Response duration was 37.5 months in those responding to therapy. The time to progression for all eighteen patients was 19.5 months. Medial survival was 25.5 months. Disease-free survival was 50% at 38 months in MCHOD responders. Grade 3 or 4 myelotoxicity was seen in 19 of 50 cycles. There were three instances of neutropenic fever, three of azotemia, two of deep vein thrombosis, and one each of community-acquired pneumonia, intracranial hemorrhage, superior vena cava syndrome, and hepatotoxicity. Late radiation-related toxicities were seen in two patients. Pre-irradiation MCHOD has activity against PCNSL, but appears to be no better than MTX monotherapy and has greater toxicity.

Key words

antineoplastic agents combined brain neoplasms cranial irradiation lymphoma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Berry MP, Simpson WJ: Radiation therapy in the management of primary malignant lymphoma of the brain. Int J Radiat Oncol Biol Phys 7: 55–59, 1981Google Scholar
  2. 2.
    Freeman CR, Shustik C, Brisson MI, Meagher-Villemure K, Dylewski I: Primary malignant lymphoma of the central nervous system. Cancer 58: 1106–1111, 1986Google Scholar
  3. 3.
    Henry JM, Heffner RR, Dillard SH, Earle RM, Davis RL: Primary malignant lymphomas of the central nervous system. Cancer 34: 1293–1302, 1974Google Scholar
  4. 4.
    Hochberg FH, Miller DC: Primary central nervous system lymphoma. J Neurosurg 68: 835–853, 1988Google Scholar
  5. 5.
    Jellinger K, Radaskiewicz TH, Slowik F: Primary malignant lymphomas of the central nervous system in man. Acta Neuropath (Berl) Suppl VI: 95: 102, 1975Google Scholar
  6. 6.
    Littman P, Wang CC: Reticulum cell sarcoma of the brain. Cancer 35: 1412–1420, 1975Google Scholar
  7. 7.
    Murray K, Kun L, Cox J: Primary malignant lymphoma of the central nervous system. J Neurosurg 65: 600–607, 1987Google Scholar
  8. 8.
    Nelson DF, Martz KL, Bonner H, Nelson JS, Newall J, Kerman HD, Thomson LW, Murray KJ: Non-Hodgkin's lymphoma of the brain: Can high-dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 23: 9–17, 1992Google Scholar
  9. 9.
    Chamberlain MC, Levin VA: Primary central nervous system lymphoma: A role for adjuvant chemotherapy. J Neuro-Oncol 14: 271–275, 1992Google Scholar
  10. 10.
    Shibamoto Y, Tsutsui K, Dodo Y, Yamabe H, Shima N, Abe M: Improved survival rate in primary intracranial lymphoma treated by high-dose radiation and systemic vincristined-oxorubicin-cyclophosphamide-prednisolone chemotherapy. Cancer 65: 1907–1912, 1990Google Scholar
  11. 11.
    DeAngelis LM, Yahalom J, Thaler HT, Kher U: Combined modality therapy for primary CNS lymphoma. J Clin Oncol 10: 635–643, 1992Google Scholar
  12. 12.
    Glass J, Gruber ML, Cher L, Hochberg FH: Pre-irradiation methotrexate chemotherapy of primary central nervous system lymphoma: Long-term outcome. J Neurosurg 81: 188–195, 1994Google Scholar
  13. 13.
    Neuwelt EA, Goldman DL, Dahlborg SA, Crossen J, Ramsey F, Roman-Goldstein S, Braziel R, Dana B: Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: Prolonged survival and preservation of cognitive function. J Clin Oncol 9: 1580–1590, 1991Google Scholar
  14. 14.
    Skarin AT, Zuckerman KS, Pitman SW, Rosenthal DS, Moloney W, Frei E, Canellos GP: High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement. Blood 50: 1039–1047, 1977Google Scholar
  15. 15.
    Turman S, Coleman M, Silver RT, Pasmantier M: High dose methotrexate with citrovorum factor in adult resistant lymphoma. Cancer 40: 2823–2828, 1977Google Scholar
  16. 16.
    Fisher RJ, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coleman CA, Miller TP: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328: 1002–1006, 1993Google Scholar
  17. 17.
    Stewart DJ, Russell N, Dennery J: Cyclophosphamide, Adriamycin, vincristine, and dexamethasone in the treatment of bulky central nervous system lymphoma. In: Walker MD, Thomas DGT (eds) Biology of Brain Tumor. Boston: Martinus Nijhoff: 433–436, 1986Google Scholar
  18. 18.
    DeAngelis LM, Yahalom J, Heinemann M-H, Cirrincione C, Thaler HT, Krol G: Primary CNS lymphoma: Combined treatment with chemotherapy and radiotherapy. Neurology 40: 80–86, 1990Google Scholar
  19. 19.
    Lachance DH, Brizel D, Gockerman J, Halperin E, Burger PC, Boyko O, Brown M, Schold C: Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: Short-duration response, multifocal intracerebral recurrence preceding radiotherapy. Neurology 44: 1721–1727, 1994Google Scholar
  20. 20.
    O'Neill BP, O'Fallon JR, Earle JD, Colgan JP, Brown LD, Krigel RL: Primary central nervous system non-Hodgkin's lymphoma: Survival advantages with combined initial therapy? Int J Radiat Oncol Biol Phys 33: 663–673, 1995Google Scholar
  21. 21.
    Schultz C, Scott C, Sherman W, Donahue B, Fields J, Murray K, Fisher B, Abrams R, Meis-Kindblom J: Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: Initial report of Radiation Therapy Oncology Group Protocol 88–06. J Clin Oncol 14: 556–564, 1996Google Scholar
  22. 22.
    Bessell EM, Punt J, Firth J, Hope T, Holland I, Lowe J: Primary non-Hodgkin's lymphoma of the central nervous system: Phase II study of chemotherapy (BVAM) prior to radiotherapy. Clin Oncol 3: 193–198, 1991Google Scholar
  23. 23.
    Brada M, Dearnaley D, Horwich A, Bloom HJG: Management of primary cerebral lymphoma with initial chemotherapy: Preliminary results and comparison with patients treated with radiotherapy alone. Int J Radiat Oncol Biol Phys 18: 787–792, 1990Google Scholar
  24. 24.
    Cher L, Glass J, Hochberg FH: Treatment of primary central nervous system lymphoma (PCNSL) with high-dose methotrexate (HDMTX) and deferred whole brain radiation therapy (WBRT). Neurology 44: A378, 1994 (abstr)Google Scholar
  25. 25.
    Ott RJ, Brada M, Flower MA, Babich JW, Cherry SR, Deehan BJ: Measurements of blood-brain barrier permeability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma. Eur J Cancer 27: 1356–1362, 1991Google Scholar
  26. 26.
    Evans WE, Hutson PR, Stewart CF, Cairnes DA, Bowman WP, Rivera G, Crom WR: Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion. Clin Pharm Therap 33: 301–307, 1983Google Scholar
  27. 27.
    Borsi JD, Moe PJ: A comparative study of the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia. Cancer 60: 5–13, 1987Google Scholar
  28. 28.
    Ervin TH, Cannellos GP: Successful treatment of recurrent primary central nervous system lymphoma with high-dose methotrexate. Cancer 45: 1556–1557, 1980Google Scholar
  29. 29.
    Pitman SW, Frei E III: Weekly methotrexate-calcium leucovorin rescue; effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS, and use in CNS non-Hodgkin's lymphoma. Cancer Treat Rep 61: 695–701, 1977Google Scholar
  30. 30.
    Loeffler JS, Ervin TJ, Mauch P, Skarin A, Weinstein HJ, Canellos G, Cassady JR: Primary lymphoma of the central nervous system: Patterns of failure and factors that influence survival. J Clin Oncol 3: 490–494, 1985Google Scholar
  31. 31.
    Pollack IF, Lunsford LD, Flickinger JC, Dameshek HL: Prognostic factors in the diagnosis and treatment of primary central nervous system lymphoma. Cancer 63: 939–947, 1989Google Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • Jon Glass
    • 1
  • Chaim Shustik
    • 2
  • Fred H. Hochberg
    • 1
  • Lawrence Cher
    • 1
  • Michael L. Gruber
    • 1
  1. 1.Massachusetts General HospitalBoston
  2. 2.Royal Victoria HospitalMontrealCanada

Personalised recommendations